Induction of the remission by use of infliximab in RA

Induction of the remission by use of infliximab in RA - Induction of the remission by use of infliximab in RA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003344

Enrollment

Registered

2010-03-23

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients at least 20 years old at enrollment 2) Patients diagnosed with RA based on the 1987 classification criteria of ACR or the 2009 classification criteria of ACR/EULAR 3) Patients who are seropositive for anti-CCP antibody 4) Patients who were treated with MTX for more than twelve weeks before enrollment 5) Patients whose DAS28-ESR score is more than 3.2 6) Patients who have expressed their informed consent in writing

Exclusion criteria

Exclusion criteria: 1) Patients who correspond to the contraindication for use of infliximab and MTX 2) Patients who are more than 70 years old at enrollment 3) Patients who have contracted RA for more than 10 years 4) Patients who are treated with more than 10mg of predonisolone 5) Other patients whom the investigator considers to be unsuitable for the study

Design outcomes

Primary

Measure	Time frame
The rate of patients who maintain their DAS28-ESR score less than 3.2 one year after discontinuance of infliximb	—

Countries

Japan

Outcome results